Key facts
- Notable investors include Audacious Capital, Venture Investors Health Fund.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Sanacor
Funding rounds
1 roundsAbout Sanacor
Developer of mitochondrial-targeted therapies designed to address mitochondrial dysfunction in cardiometabolic diseases and reverse diabetic cardiovascular disease. The company offers a mitochondrial biology-based therapeutic development platform and research-driven drug discovery capabilities, enabling pharmaceutical and biomedical researchers to develop disease-modifying treatments for diabetic complications and related disorders.
- Industry
- Biotechnology
- Sector
- Healthcare
- HQ
- Milwaukee, WI, United States
- Founded
- 2023
- Employees
- 5
- Website
- sanacor.com/
- Ownership
- Privately Held (backing)
Sanacor doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sanacor shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sanacor in its N-PORT filings yet. We sweep new filings monthly.